FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| 1AD | $0.01 | 0.00% | $0.02 | $0.00 |
|
||
| ACR | $0.02 | 0.00% | $0.03 | $0.01 |
|
||
| ACW | $0.04 | 0.00% | $0.07 | $0.02 |
|
||
| ADO | $0.01 | 0.00% | $0.03 | $0.01 |
|
||
| AFP | $3.19 |
|
$3.37 | $2.20 |
|
||
| AGN | $0.26 |
|
$0.89 | $0.19 |
|
||
| ARX | $0.70 |
|
$0.80 | $0.35 | 141.7 |
$0.82 |
|
| AVH | $1.09 |
|
$3.38 | $1.00 |
$1.275 |
|
|
| BIO | $0.43 |
|
$0.72 | $0.39 | 28.7 |
$1.00 |
|
| BOT | $0.12 |
|
$0.54 | $0.10 |
|
||
| COV | $0.61 | 0.00% | $0.90 | $0.31 |
|
||
| CSL | $152.19 |
|
$275.79 | $150.21 | 16.0 |
$207.477 |
|
| CUV | $10.72 |
|
$14.00 | $9.41 | 15.4 |
$16.50 |
|
| DXB | $0.51 |
|
$0.79 | $0.34 |
|
||
| GSS | $0.13 |
|
$0.69 | $0.13 |
$0.55 |
|
|
| IDT | $0.05 | 0.00% | $0.12 | $0.05 |
|
||
| ILA | $0.39 |
|
$0.63 | $0.12 |
|
||
| IMM | $0.38 |
|
$0.47 | $0.22 |
$1.075 |
|
|
| IMU | $0.26 |
|
$0.46 | $0.01 |
$0.82 |
|
|
| IVX | $0.08 | 0.00% | $0.20 | $0.08 |
|
||
| LGP | $0.13 | 0.00% | $0.15 | $0.10 |
|
||
| MAP | $0.09 | 0.00% | $0.27 | $0.07 |
$0.21 |
|
|
| MSB | $2.45 |
|
$3.31 | $1.52 | -86.1 |
$4.45 |
|
| MVP | $0.48 |
|
$0.92 | $0.42 |
$0.84 |
|
|
| MYX | $2.67 |
|
$7.31 | $2.60 |
|
||
| NEU | $13.57 |
|
$22.99 | $8.61 | 98.7 |
$24.567 |
|
| NUZ | $0.10 | 0.00% | $0.19 | $0.08 |
$0.28 |
|
|
| OCC | $0.94 |
|
$1.70 | $0.86 |
|
||
| OSL | $0.69 |
|
$2.09 | $0.00 |
|
||
| PAR | $0.31 | 0.00% | $0.66 | $0.26 |
$0.65 |
|
|
| PER | $0.01 | 0.00% | $0.02 | $0.01 |
|
||
| PNV | $0.93 |
|
$2.07 | $0.92 | 40.4 |
$1.977 |
|
| PYC | $1.48 |
|
$1.76 | $0.85 |
$2.30 |
|
|
| RAC | $2.25 |
|
$4.90 | $0.92 |
|
||
| RCE | $0.59 |
|
$0.73 | $0.28 |
|
||
| SNT | $0.03 | 0.00% | $0.10 | $0.02 |
$0.06 |
|
|
| SPL | $0.48 |
|
$0.50 | $0.08 |
|
||
| TLX | $9.08 |
|
$31.97 | $9.05 | -558.0 |
$27.24 |
|
| TRP | $0.19 |
|
$0.48 | $0.17 |
|
||
| VIT | $0.05 | 0.00% | $0.14 | $0.05 |
|
||
| ZNO | $0.07 | 0.00% | $0.18 | $0.03 |
|
17.1% Previous Stories
Dr Boreham’s Crucible: Chimeric Therapeutics
May 26 2023
Tim Boreham reports cancer treatment biotech Chimeric has struggled, but may yet have a sting in its tail
Avita Medical Preps For Enlarged US Opportunity
May 17 2023
Brokers review first quarter results and pending regulatory approvals for Avita Medical
Dr Boreham’s Crucible: Radiopharm Theronostics
Apr 13 2023
Cancer detection biotech Radiopharm Theronostics is planning to list on the Nasdaq, and not without good reason, Tim Boreham explains
Dr Boreham’s Crucible: Avita Medical
Mar 29 2023
Tim Boreham highlights the global addressable market opportunity for Avita Medical’s skin graft technology, made famous by the Bali bombings
Telix Pharmaceuticals’ Pipeline Full Of Promise
Mar 21 2023
Following FY22 results for Telix Pharmaceuticals brokers remain Buy-rated in light of an extensive pipeline of new products under development
FDA Approval Puts Rocket Under Neuren Shares
Mar 16 2023
Amidst a sea of red, the Neuren share price has skyrocketed in recent days following a world first approval for the biotech’s treatment of Rett syndrome
Dr Boreham’s Crucible: Actinogen Medical
Nov 30 2022
Actinogen Medical is a biotech with a potentially “gazillion” dollar opportunity in its Alzheimer’s drug
Dr Boreham’s Crucible: Qbiotics Group
Nov 09 2022
Having brought a canine cancer treatment to market, Qbiotic’s focus has returned to treating two-legged cancers including melanoma and other difficult-to-treat cancers
Latest News
| 1 |
ASX Winners And Losers Of Today – 12-02-26Feb 12 2026 - Daily Market Reports |
| 2 |
Rudi Interviewed: February Is Less About EarningsFeb 12 2026 - Rudi's View |
| 3 |
FNArena Corporate Results Monitor – 12-02-2026Feb 12 2026 - Australia |
| 4 |
Australian Broker Call *Extra* Edition – Feb 12, 2026Feb 12 2026 - Daily Market Reports |
| 5 |
The Short Report – 12 Feb 2026Feb 12 2026 - Weekly Reports |